Inspira Technologies Supplies Innovative Respiratory Systems Across the U.S.

Inspira Technologies Oxy B.H.N. Ltd., traded under NASDAQ with the symbols IINN and IINNW, is set to make waves in the medical technology sector with the delivery of its state-of-the-art INSPIRA™ ART100 systems to Glo-Med Networks Inc., a prominent distributor based in the United States. This strategic move marks a significant milestone in Inspira’s mission to enhance respiratory support technology.

Having received a purchase order from Glo-Med, Inspira Technologies has shipped the initial batch of INSPIRA ART100 systems, which are intended for deployment across various hospitals on the eastern seaboard of the U.S. Notably, one of the key targets for distribution is a leading hospital in New York, recognized as being among the top 15 percent of cardiothoracic programs nationwide. This collaboration not only aims to promote immediate utilization of the ART100 but also lays the groundwork for future partnerships in advancing respiratory care.

The INSPIRA ART100 system itself represents a transformational advancement in the realm of cardiopulmonary bypass technology. Designed in close collaboration with top U.S. medical professionals, this innovative system integrates sophisticated technology with user-friendly design to optimize patient outcomes during critical medical procedures. The ART100 is designed to work in tandem with HYLA™, a cutting-edge blood monitoring technology that continuously assesses patients' conditions in real time, thus enhancing clinical decision-making processes.

Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, expressed his vision for the deployment, stating, "We see this as merely the first deployment step in Inspira's quest to revolutionize acute respiratory care with our groundbreaking technology and superior products that we believe will follow this initial distribution." This sentiment reflects the continued commitment by Inspira to reshape healthcare standards and improve patient care through innovative solutions.

The INSPIRA ART100 is just one component of Inspira's broader lineup of advanced respiratory technologies, including its flagship Augmented Respiration Technology (INSPIRA ART), which is poised to disrupt the $19 billion mechanical ventilation market. This system has been specifically developed to stabilize patients with declining oxygen levels swiftly, allowing them to remain conscious during treatment, a significant improvement over traditional mechanical ventilators.

Inspira's commitment to innovation is further highlighted by the ongoing clinical evaluations of HYLA™ technology at Sheba Hospital, rated ninth globally by Newsweek. This blood sensor technology aims to augment existing monitoring systems and better inform physicians of any critical changes in their patients' conditions during operations such as open-heart surgeries. The company plans to submit this technology for FDA clearance in 2025, a move that could further bolster its position within the medical industry.

Furthermore, the INSPIRA ART100 system has already received FDA 510(k) clearance for use in cardiopulmonary bypass procedures, along with Israeli AMAR certification covering both extracorporeal membrane oxygenation and cardiopulmonary bypass approaches. Inspira’s suite of products, which also includes the INSPIRA™ Cardi-ART portable device and the VORTX orbiting oxygen delivery system, are currently in various stages of development, aimed at enhancing patient treatment experiences through technological advancement.

In summary, this collaboration with Glo-Med Networks Inc. and the delivery of INSPIRA™ ART100 systems signals a bold step forward for Inspira Technologies as it strives to redefine respiratory medicine, showcasing not only technological prowess but also a robust commitment to improving patient outcomes. For additional details regarding Inspira and its innovative offerings, visitors are encouraged to explore their corporate website at Inspira Technologies.